Dr. Reddy's Laboratories Ltd. announced the launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of ALIMTA® (pemetrexed for injection) in the U.S. Market approved by the U.S. Food and Drug Administration. The ALIMTA® brand and generic had U.S. sales of approximately $1,239 million MAT for the most recent twelve months ending in March 2022 according to IQVIA Health. Dr. Reddy's Pemetrexed for Injection is supplied in 100 mg and 500 mg single-dose vials.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,350 INR | +0.98% | +1.55% | +9.52% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.52% | 12.68B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
-3.40% | 157B |
- Stock Market
- Equities
- DRREDDY Stock
- News Dr. Reddy's Laboratories Limited
- Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration